Participated · Series A · Mar 2018

Singlera Genomics develops non-invasive genetic tests for early-stage cancer detection using proprietary technologies including single cell sequencing, DNA methylation sequencing and machine learning. The company operates R&D centers and business operations in La Jolla, California and Shanghai, China. Its core platforms include TiTanSeq™ and MONOD™, and it also provides customized next-generation sequencing services to pharmaceutical companies and medical research institutions. Singlera intends to use the funds from the recent financing to expand development and commercialization of its non-invasive tests and to run clinical validation studies. The company plans to further expand its research facilities and to extend its TiTanSeq and MONOD platforms into new product lines addressing early cancer detection, diagnosis and personalized treatment. Singlera was co-founded in July 2014 by Yuan Gao, PhD; Professor Kun Zhang; Jiangli Zhang (CEO); Qiang Liu (COO); and Rui Liu (CTO). Singlera Genomics develops non-invasive genomic sequencing tests for cancer and other genetic diseases. Its core offerings include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening and other genetic disease diagnostics. The company also provides customized technology and scientific research services. Singlera holds proprietary technologies in single-cell sequencing, DNA methylation and bioinformatics. In 2016 it raised US$20m in a Series A to expand development and commercialization of its tests. The company was co-founded in July 2014 in San Diego and is based in Shanghai and La Jolla, CA.